In our latest Preview from the American Society of Hematology, we’re using the dragon’s…
What to watch out for in DDR, epigenetic therapies, and other hot topics
What we can learn from scientific talks at WCLC in order to improve clinical development
Important new preclinical data sets the scene for PDAC
Highlighting some outstanding research to take note of
Tackling intractable cancers with a novel and creative approach to the problem
Have you ever wondered why some anti-cancer agents do well and others poorly – even with similar…
Initial learnings on KRAS presentations at AACR23
W2W4 on the TPD front
Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…
What will be the emerging products and regimens to watch out for in aggressive lymphomas?
A novel approach to targeting an intractable oncogene
Beyond KRAS - targeting another of the four horsemen of the apocalypse
Can we overcome resistance checkpoint blockade with novel approaches to DDR?
A look at promising new approaches in SCLC
What can we learn from IO trials in lung cancer to help us evaluate TIGIT's prospects?
5 key and novel early areas of development which stood out to us at AACR22
Cracking the tumour code
What to watch out for in 2022
A dozen early stage biotechs in the RAS/RAF pathway to watch out for
A number of new developments to consider in the KRAS niche
It's time to tackle some intractable targets in oncology and elsewhere...
What are Novartis up to these days with their oncology pipeline and what are they excited about?
Which abstracts stood out in the initial run through of the data? Includes some hidden gems and surprises!
New developments on the KRAS and SHP2 front
A look at the subtleties and nuances under the hood of the Arvinas PROTACs
Emerging areas in cool new science around targeted therapies
What to watch out for in the protein degradation niche
Degrading oncogenic proteins with novel bacterial approaches
Post SABCS analysis of a key topic and cancer driver
W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on
New developments in the BTK niche offer fresh insights on progress
new approaches to applying translational research to the clinic in oncology R&D
Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to…
What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?
Ten intriguing novel agents in early development to watch out for
Reprogramming the tumour microenvironment - can it be done and if so, how and what should be targeted?
In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours
Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines
A look at off Broadway abstracts on early new product development and scientific findings of interest
It's time for an update on new participants to the runners and riders in CLL and NHL. Some interesting findings with BTK inhibitors to consider here!
A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC
How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...
How do mission critical oncogenes cooperate and act in concert in cancer?
If we want to be able to drug oncogenes such as MYC then we need to figure out how they work and function to find the achilles heel
Proteins change shape, both temporally and also in response to different conditions. Can we use this information to develop novel cancer therapeutics? One company is exploring ways of achieving this.
Looking under the hood to find biomarkers of response and outcomes, ,
A potential role for epigenetic therapies in straddling the divide between transcription factors and the immune system...
A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?
The bromodomain market has exploded in recent years with many more agents in the development. Are they all the same though?
Understanding the regulatory circuitry that controls cell state and differentiation may turn out to be groundbreaking research that changes the way we think about targeting and treating cancer.
What can we learn about the MYC transcription factor and oncogene in order to turn it into a viable target in oncology R&D?
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
Targeting MYC and bromodomains is an emerging area of research as we learn more about super enhancer transcription factor clusters around oncogenes that drive cancer.